Cantor Fitzgerald Maintains Elutia(ELUT.US) With Buy Rating, Raises Target Price to $11
Cantor Fitzgerald analyst Ross Osborn maintains $Elutia(ELUT.US)$ with a buy rating, and adjusts the target price from $5 to $11.According to TipRanks data, the analyst has a success rate of 19.5% and
Express News | Elutia Shares Are Trading Lower After the Company Announced a $13.26 Million Registered Direct Offering
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersScinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:ND
Express News | Elutia Received FDA Clearance of EluPro
Express News | Elutia Announces $13.26M Registered Direct Offering Of 3.175M Shares Of Class A Stock At $3.40/Share And 725K Prefunded Warrants To Purchase 725K Shares At $3.399/Share
Express News | Elutia Plans Nationwide Elupro Launch in H2 2024
Express News | Elutia Announces $13.26 Million Registered Direct Offering
Express News | Elutia Announces FDA Clearance of Elupro®: The First Antibiotic-Eluting Bioenvelope Designed to Protect Patients With Implantable Cardiac Pacemakers and Defibrillators
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersElutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. The market value of their outstanding shares is at $104.9 million. Trinity Biotech (NASDAQ:TRIB) stock rose 20.6
Elutia | 10-Q: Quarterly report
Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024
SILVER SPRING, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, is excited to announce its participation in the upco
Earnings Call Summary | Elutia(ELUT.US) Q1 2024 Earnings Conference
The following is a summary of the Elutia, Inc. (ELUT) Q1 2024 Earnings Call Transcript:Financial Performance:Elutia reported Q1 revenue of $6.7 million, which represented substantial growth.The compan
Elutia Is Maintained at Overweight by Cantor Fitzgerald
Elutia Is Maintained at Overweight by Cantor Fitzgerald
Elutia Price Target Cut to $5.00/Share From $6.00 by Cantor Fitzgerald
Elutia Price Target Cut to $5.00/Share From $6.00 by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on Elutia, Lowers Price Target to $5
Elutia Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 70.65% Cantor Fitzgerald $6 → $5 Maintains Overweight 11/14/2023 104.78% Cantor Fitzgerald $8 →
Elutia Q1 2024 GAAP EPS $(0.75) Misses $(0.41) Estimate, Sales $6.694M Beat $6.100M Estimate
Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.41) by 82.93 percent. This is a 222.95 percent decrease over earnings of $0.61 pe
Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, Vs. Street Est of $6.1M
04:23 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M
Press Release: Elutia Announces First Quarter 2024 Results: SimpliDerm(R) Sales Increase 55%, CanGaroo(R)RM on Track for Second Quarter 2024 FDA Clearance
Elutia Announces First Quarter 2024 Results: SimpliDerm(R) Sales Increase 55%, CanGaroo(R)RM on Track for Second Quarter 2024 FDA Clearance SILVER SPRING, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Elutia
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that it will release its first quart
No Data